
    
      The objective of the combination therapy part of this study will be to investigate the safety
      and tolerability of AZD6244 given in combination with docetaxel as 2nd line therapy in
      Japanese patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage
      IIIB-IV). In addition, the pharmacokinetic profile of AZD6244 and docetaxel will be
      investigated.

      The objective of the monotherapy part of this study will be to investigate the safety and
      tolerability of AZD6244 given as a monotherapy in Japanese patients with advanced solid
      malignancies. In addition, the pharmacokinetic profile of monotherapy AZD6244 will be
      investigated.
    
  